NeurogeneNGNE
Recorded

Neurogene 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration22 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Debjit ChattopadhyaySenior Managing Director

What time is it? Good morning, and thank you for joining Guggenheim's third annual Healthcare Innovation Conference. I'm Debjit, one of the therapeutic analysts, and my privilege to host Christine Mikail, President and CFO of Neurogene. Thank you for making time for us.

Christine MikailPresident and CFO

Thanks for having me, Debjit.

Debjit ChattopadhyaySenior Managing Director

In case people are unfamiliar with Neurogene, I'll let you do a very quick intro, and then we can get into the meat of the things.

Christine MikailPresident and CFO

Sure. Neurogene is a gene therapy company focusing on developing treatments for children and families with rare neurological diseases. Neurogene's lead candidate that is right on the precipice of outcomes for a pivotal registrational trial is in a trial for Rett syndrome. It's called the Embolden trial, with results expected in the second half of next year. We presented data earlier this year in June from the phase I, phase II trial, which had 10 patients, and saw really quite exceptional benefits for these patients. Every single one of these patients had a benefit that was both a functional gain and a global clinical improvement that was evident in looking at the patients. In the trial itself, we're measuring outcomes for Rett syndrome patients, so milestones, the numbers of milestones really, really matter.

Christine MikailPresident and CFO

Not only did 100% of patients get a milestone, seven out of 10 of those patients had more than one milestone. Seven out of 10 actually had a multi-domain change with respect to those milestones. With measuring the 12-month outcome, which is what the pivotal endpoint is, in the Embolden trial, 80% of patients met that bar at 12 months. We are very, very pleased to see it, and we had the 10 patients were both pediatric and adolescent patients, so both severity, age, none of those really mattered as it related to outcomes. Everyone actually did have a benefit. That, I think we are very pleased with the results, and we are looking forward to the outcome in the second half of next year.

Debjit ChattopadhyaySenior Managing Director

You brought up the Embolden trial. You over-enrolled. You have 25 patients as opposed to 20.

Debjit ChattopadhyaySenior Managing Director

Two things there. Is that the unmet need, or was it driven by the data that were presented and the implications of the data for the patients?

Christine MikailPresident and CFO

That is a great question, Debjit. What we saw initially, we started off with an N of 20, and what we saw is patients were actually very interested in getting onto the trial, such that we actually ended up over-enrolling the trial. We ended up with 25 patients, mostly because patients wanted to get on drug and allowed us to develop a really good dataset. Yes, there is an unmet need, but you would think in a gene therapy where the disease is not a neurodegenerative disease, it is a neurodevelopmental disease, and it takes time, right? It is not like there is a rush to treatment. We were actually very pleasantly surprised to see that patients really wanted to get on drug, and it allowed for the over-enrollment of trial.

Christine MikailPresident and CFO

It just speaks to the nature of patients and families are waiting, and frankly, there is a drug that is already approved to treat Rett syndrome. It is a symptom modifier named DAYBUE. It has done an excellent job of setting the stage for a future gene therapy and a disease-modifying drug, but there is no therapy available today that addresses the root cause of the disease. Gene therapy will do so, and that actually is what people, I think, are interested in now.

Debjit ChattopadhyaySenior Managing Director

Rett is not a neurodegenerative disease.

Debjit ChattopadhyaySenior Managing Director

No. That gives you the flexibility to treat across the spectrum.

Debjit ChattopadhyaySenior Managing Director

But is there a sweet spot if you could treat earlier in terms of the number of milestones they could land up gaining, and what is the strategy around that?

Christine MikailPresident and CFO

Excellent question. Because it is not a neurodegenerative disease, neurons do not die, which means neurons are available to actually receive a benefit in the future. What does that mean as it relates to treating patients? We can treat pediatric patients. We can treat adolescent and adult patients because it is not like there is not an avenue for benefit. Biologically, plausibility suggests that each patient can actually garner a benefit from treatment. However, as it relates to your question of like, where would you see a meaningful benefit, I think the good news is we have seen it across all 10 of our patients that suggests biological plausibility has shown benefit in all across the spectrum, both in disease severity and age. But pediatric patients are still very neuroplastic, right?

Christine MikailPresident and CFO

There is an ability to change the trajectory of the disease potentially, so treating younger, especially for whether it's a neurodevelopmental disorder that isn't neurodegenerative, treating younger is going to benefit patients, hopefully more so than possibly older patients. But the nice thing about the disease is there is an ability to benefit across all ages and severity spectrums for the disease itself.

Debjit ChattopadhyaySenior Managing Director

Investor conversations on this are sort of centered around one issue, which has been the mode of delivery, right? You are using a slightly more invasive approach versus your competitor. Could you unpack in terms of ICV versus intrathecal? Is there fundamentally a difference other than maybe you land up with much better efficacy over the long term if you use ICV?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day